Issue link: http://www.e-digitaleditions.com/i/730359
2. Muthu DC. Pulmonary tuberculosis: Its etiology and treatment—Record of twenty-two years observation and work in open-air sanatoria. London; Bailliére, Tindall and Cox, 1922. 3. Brewis RAL. Classic papers in asthma. London; Science Press, 1990. 4. Moeller AAM. Thérapeutique locale des maladies de l'appareil respiratory par les inhalations médicamenteuses et les pratiques aérothérapiques; Librairie J-B Bailliére, Paris 1882. 5. Miller WF. Aerosol therapy in acute and cronic respira- tory diseas. Arch Intern Med; 131:148-155, 1973. 6. Anderson PJ. A history of aerosol therapy. Respir Care; 50(9):1139-1150, 2005. 7. Sanders M. Sales-Girons pulverisateur and Pneumostat nebulizer. By permission of The Inhalatorium. http://www.inhalatorium.com. 8. Nikander K, Sanders M. The early evolution of nebu- lizers. MedicaMundi; 54(3):7-53, 2010. 9. Dessanges JF. A history of nebulisation. J Aerosol Med; 14(1):65-71, 2004. 10. Waldenburg L. Die inhalation der zerstäubten Flüs- sigkeiten sowie der dämpfe und gase in ihrer wirkung auf die krankheiten det athmungsorgane. Lehrbuch der Res- piratorischen Therapie. Druck und Verlag von Georg Reimer, Berlin, 1864. 11. Solis-Cohen S. Inhalation: Its therapeutics and prac- tice. Philadelphia, 1867. 12. Daniels T, Mills N, Whitaker P. Nebuliser systems for drug delivey in cystic fibrosis. Cochrane Database Syst Rev, Apr 30;4, 2013:CD007639. doi: 10.1002/14651858. CD007639.pub2. 13. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance: Effects of dilu- ent volume, nebulizer flow, and nebulizer brand. Chest; 110(2):498-505, 1996. 14. Sterk PJ, Plomp A, van de Vate JF, Quanjer PH. Phys- ical properties of aerosols produced by several jet- and ultrasonic nebulizers. Bull Europ Physiopath Resp; 20(1):65-72, 1984. 15. Lord Rayleigh (J.W. Strutt). On the instability of jets. Proc London Math Soc; 10:4-13, 1878. 16. Weber C. Disintegration of liquid jets. Z. Angew. Math Mech; 11:136-159, 1931. 17. Nerbrink O, Dahlback M, Hansson HC. Why do medical nebulizers differ in their output and particle char- acteristics? J Aerosol Med; 7:259-276, 1994. 18. Smye SW, Jollie MI, Littlewood JM. A mathematical model of some aspects of jet nebulizer performance. Clin Phys Physiol Meas; 12(3):289-300, 1991. 19. O'Callaghan C, Barry PW. The science of nebulised drug delivery Thorax; 52(Suppl 2):S31-S44, 1997. 20. Leung K, Louca E, Coates AL. Comparison of breath- enhanced to breath-actuated nebulizers for rate, consis- tency and efficiency. Chest; 126(5):1619-1627, 2004. 21. Yeo LY, Friend JR, McIntosh MP, Meeusen ENT, Morton DAV. Ultrasonic nebulization platforms for pul- monary drug delivery. Expert Opin. Drug Deliv; 7(6):663-679, 2010. 22. LeBrun PPH, deBoer AH, Heijerman HGM, Fri- jlink HW. A review of the technical aspects of drug nebu- lization. Pharm World Sci; 22(3):75-81, 2000. 23. Qi A, Friend JR, Yeo LY, Morton DA, McIntosh MP, Spiccia L. Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization. Lab Chip; 9:2184-2193, 2009. 24. Zierenberg G. Optimizing the in vitro performance of Respimat ® . J Aerosol Med; 12:S19-S24, 1999. 25. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat ® Soft Mist Inhaler™ and pres- surized metered dose inhalers. J Aerosol Med; 18:273- 282, 2005. 26. De Boer AH, Wissik J, Hagedoorn P, Heskamp I, de Kruijf W, Bunder R, Zanen P, Munnik P, van Rijn C, Frijlink HW, In vitro performance testing of the novel Medspray ® wet aerosol inhaler based on the principle of Rayleigh break-up. Pharm Res; 25(5):1186-1192, 2008. 27. Munnik P, de Boer AH, Wissink J, Hagedoorn P, Heskamp I, de Kruijf W, van Rijn CJM, Frijlink HW, Zanen P. In vivo performance testing of the novel Med- spray ® wet aerosol inhaler. J Aerosol Med Pulm Drug Del; 22(4):317-321, 2009. 28. Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv; 5(2):114-119(6), 2008. 29. Ghanzanfari T, Abdelbary MAH, Zhiyi D, Talor MG. The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int J Pharm; 339(1- 2):103-111, 2007. 30. Skaria S, Smaldone GC. Omron NE U22: Compari- son between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Del, 23(3):173-180, 2010. Ola Nerbrink, PhD is the owner of Respiron Consulting AB, Building 403, Medicon Village, 223 81, Lund, Sweden, Tel: +46 76 16 02 70, info@respironconsulting.com. Website: www.respironconsulting.com. He is also CEO of the Medicon Valley Inhalation Consortium, MVIC AB, Build- ing 403, Medicon Village, 223 81, Lund, Sweden, Ola.ner brink@mvic.se. Website: www.mvic.se. 14 OCTOBER2016 Inhalation